MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Anthera Pharmaceuticals Company Profile (NASDAQ:ANTH)

Consensus Ratings for Anthera Pharmaceuticals (NASDAQ:ANTH) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $11.00 (247.00% upside)

Analysts' Ratings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016FBR & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Piper JaffrayLower Price TargetOverweight$14.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Citigroup Inc.Lower Price Target$15.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/8/2015SunTrustInitiated CoverageBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q1($0.28)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4($0.27)($0.18)$1.92 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2015Q315($0.25)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.28)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.31)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015($0.33)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014($0.39)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2014($0.49)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.46)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014($0.47)($0.48)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2013Q412($0.15)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Anthera Pharmaceuticals (NASDAQ:ANTH)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.30)($0.30)($0.30)
Q2 20162($0.30)($0.29)($0.30)
Q3 20162($0.30)($0.29)($0.30)
Q4 20162($0.28)($0.26)($0.27)
(Data provided by Zacks Investment Research)
Dividend History for Anthera Pharmaceuticals (NASDAQ:ANTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/13/2015Colin HislopinsiderSell12,500$5.31$66,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Colin HislopInsiderSell5,000$5.38$26,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2015Debra OdinkCTOSell1,205$6.15$7,410.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2013David E ThompsonDirectorBuy12,500$0.53$6,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2013Bogdan DziurzynskiDirectorBuy1,250$0.59$737.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2013Orbimed Advisors LlcDirectorBuy712,500$0.66$470,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/25/2013Orbimed Advisors LlcDirectorBuy220,250$0.65$143,162.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Anthera Pharmaceuticals (NASDAQ:ANTH)
DateHeadline
06/27/16 07:15 AMNext Weeks Broker Price Targets For Anthera Pharmaceuticals, Inc. (ANTH) - Fiscal Standard
06/26/16 07:32 AMStrong Sell Calls Recommendations For Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) At 0 - Investor Newswire
06/24/16 07:41 PMMyocardial Infarction Therapeutics Market Growth 2016 Forecast to 2022
06/24/16 02:29 PMAnthera Pharmaceuticals, Inc. (ANTH) Updated Price Targets - FTSE News
06/24/16 08:46 AMThe 2016 Report on Myocardial Infarction World Market Segmentation and Major Players Analysis 2022
06/22/16 07:39 PMAnthera Pharmaceuticals, Inc. (NasdaqGM:ANTH) Stock Momentum Hits Weakness - CML News
06/21/16 07:18 AMRecently Issued Stock Ratings For Anthera Pharmaceuticals, Inc. (ANTH) - Fiscal Standard
06/20/16 08:58 AMStock Highlights: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), American Water Works Company, Inc. (NYSE:AWK ... - KC Register
06/19/16 07:13 AMThis Weeks Broker Views For Anthera Pharmaceuticals, Inc. (ANTH) - Fiscal Standard
06/15/16 07:36 PMRecent Study on Exocrine Pancreatic Insufficiency Market with Size and Share Deep Analysis
06/15/16 07:36 PMAnthera Pharmaceuticals : Announces Presentation at JMP Securities Life Sciences Conference
06/15/16 03:29 PMAnthera Pharmaceuticals Announces Presentation at JMP Securities Life Sciences Conference - [at noodls] - c3d0dd03-d563-4bba-8b98-3c4dead9a915.pdf June 15, 2016 HAYWARD, Calif., June 15, 2016 -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the Company's attendance at the JMP Securities Life ...
06/05/16 10:24 AMAnthera Pharmaceuticals Incorporated (NASDAQ:ANTH) Shorted Shares Increased By 10.63% - HNN
06/05/16 10:24 AMAnthera Pharmaceuticals, Inc. (ANTH) Broker Price Targets For The Coming Week - Share Trading News
06/04/16 10:57 AMHealthcare Moving Stocks: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) , Cardiovascular Systems, Inc. (NASDAQ ... - Is stories
06/03/16 02:33 PMBroker Analysis: Anthera Pharmaceuticals, Inc. (ANTH) - Share Trading News
06/03/16 10:59 AMAnthera Pharmaceuticals Inc Just Recorded A Sigfniciant Increase - HNN
06/03/16 09:54 AMCan the Rally in Anthera (ANTH) Shares Continue? -
06/02/16 02:36 PMAnthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Quarterly EPS Estimate At $-0.34 - Investor Newswire - Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Quarterly EPS Estimate At $-0.34Investor NewswireFirst Call stated that Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) can touch $10.75 in coming one year. For the next quarter, the per-share earnings target is $-0.34 and for ongoing fiscal at $-1.25. EPS target for next year is $-1.25 versus the mean ...
06/01/16 10:54 AMStock Review and Earnings Check on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - HNN - Stock Review and Earnings Check on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Anthera Pharmaceuticals, Inc.and more »
05/30/16 11:20 PMAnthera Pharmaceuticals : Announces Presentation at Jefferies Healthcare Conference - 05/09 Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quart.. 04/30 ANTHERA PHARMACEUTICALS INC: Entry into a Material Definitive Agreement, Change.. 04/28 ANTHERA PHARMACEUTICALS: Greenphire Empowers Orphan Drug and Rare Disease ...
05/30/16 07:10 PMAnthera Pharmaceuticals Announces Presentation at Jefferies Healthcare Conference - [at noodls] - 20a621af-7a32-4795-81b3-f6f09a14ea2f.pdf May 30, 2016 HAYWARD, Calif., May 30, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the Company's attendance at the Jefferies ...
05/30/16 07:10 PMAnthera Pharmaceuticals Announces Presentation at Jefferies Healthcare Conference - [at noodls] - 20a621af-7a32-4795-81b3-f6f09a14ea2f.pdf May 30, 2016 HAYWARD, Calif., May 30, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the Company's attendance at the Jefferies ...
05/30/16 02:38 PMBrokerages Expect Anthera Pharmaceuticals Inc (NASDAQ:ANTH) to Announce ($0.30) Earnings Per Share - Let Me Know About This - Brokerages Expect Anthera Pharmaceuticals Inc (NASDAQ:ANTH) to Announce ($0.30) Earnings Per ShareLet Me Know About ThisAnthera Pharmaceuticals logo Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) have earned an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports.Analysts Set 1-Year Price Target Of $11 On Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) StockVanguard Tribuneall 6 news articles »
05/27/16 12:49 AMExocrine Pancreatic Insufficiency Market to Reach US $2.85 Bn by 2023; Difficult Drug Approval Procedures Could Hamper Growth - Transparency Market Research Report Added "Exocrine Pancreatic Insufficiency Market" to its database. Albany, NY -- (SBWIRE) -- 05/26/2016 -- Transparency Market Research has published a new market report titled, "Exocrine Pancreatic Insufficiency Market ...
05/25/16 12:51 AMEarnings Review and Stock Rundown for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Wall Street Hints and News - Earnings Review and Stock Rundown for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Anthera Pharmaceuticals, Inc.and more »
05/23/16 02:35 PMAnthera Pharmaceuticals Incorporated (NASDAQ:ANTH) Shorted Shares Decreased By 3.35% - Wall Street Hints and News - Anthera Pharmaceuticals Incorporated (NASDAQ:ANTH) Shorted Shares Decreased By 3.35%Wall Street Hints and NewsAnthera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The company has a ...and more »
05/23/16 07:27 AMStock Rating Review for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Wall Street Hints and News - Stock Rating Review for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH). Covering ...and more »
05/20/16 07:44 PMShining on Major News: The LGL Group, Inc. (NYSEMKT:LGL), Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH ... - KC Register - Shining on Major News: The LGL Group, Inc. (NYSEMKT:LGL), Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH ...KC RegisterAnthera Pharmaceuticals, Inc. (NASDAQ:ANTH) reported financial results for the first quarter ended March 31, 2016. General and administrative expenses for the quarter ended March 31, 2016 totaled $2.2 million, compared to $1.9 million in the same ...
05/19/16 05:57 PMETF’s with exposure to Anthera Pharmaceuticals, Inc. : May 19, 2016 -
05/19/16 02:32 PMHow are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular ... - PR Newswire (press release) - How are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular ...PR Newswire (press release)Ahead of today's session, ActiveWallSt.com's presents four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Intra-Cellular Therapies Inc.and more »
05/18/16 07:39 PMShare Recap and Earnings Focus on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Wall Street Hints and News - Share Recap and Earnings Focus on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Anthera Pharmaceuticals, ...and more »
05/18/16 07:39 PMAnthera Pharmaceuticals Inc (NASDAQ:ANTH) Stocks Overview - News Oracle - Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Stocks OverviewNews OracleBy looking at Anthera Pharmaceuticals Inc (NASDAQ:ANTH) YTD (year to date) performance, the stock shows Negative value of -26.72%. If the YTD value is Negative, it means that the stock is trading poorly. If the YTD value is Positive, this means the ...Anthera Pharmaceuticals Incorporated (NASDAQ:ANTH) Shorted Shares Decreased By 3.35%Wall Street Hints and Newsall 2 news articles »
05/18/16 10:18 AMAnthera Pharmaceuticals, Inc. :ANTH-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/17/16 02:37 PMIs Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Going to Burn These Institutional Investors? - Wall Street Hints and News - Is Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Going to Burn These Institutional Investors?Wall Street Hints and NewsAnthera Pharmaceuticals Inc (NASDAQ:ANTH) institutional sentiment decreased to 1.19 in Q4 2015. Its down -0.96, from 2.15 in 2015Q3. The ratio has dropped, as 38 funds increased and started new stock positions, while 32 reduced and sold stakes in ...
05/16/16 07:32 AMConsensus Rating Review for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Wall Street Hints and News - Consensus Rating Review for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1 on shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/12/16 01:02 AMCymaBay Reports First Quarter 2016 Financial Results - Paul Truex, currently President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) with more than 20 years of experience in senior operational positions in the biotechnology and pharmaceutical industries. Robert Weiland, who last ...
05/11/16 07:53 PMFY2020 EPS Estimates for Anthera Pharmaceuticals Inc (ANTH) Increased by Analyst - Washington News Wire - Washington News WireFY2020 EPS Estimates for Anthera Pharmaceuticals Inc (ANTH) Increased by AnalystWashington News WireAnthera Pharmaceuticals logo Anthera Pharmaceuticals Inc (NASDAQ:ANTH) – Investment analysts at Jefferies Group increased their FY2020 earnings per share (EPS) estimates for shares of Anthera Pharmaceuticals in a report issued on Monday, ...HC Stocks Broker Alerts: Galena Biopharma Inc (GALE), Arrowhead Pharmaceuticals Inc (ARWR), Anthera ...share market updates (press release)all 2 news articles »
05/11/16 02:46 PMHC Stocks Broker Alerts: Galena Biopharma Inc (GALE), Arrowhead Pharmaceuticals Inc (ARWR), Anthera ... - share market updates (press release) - share market updates (press release)HC Stocks Broker Alerts: Galena Biopharma Inc (GALE), Arrowhead Pharmaceuticals Inc (ARWR), Anthera ...share market updates (press release)Shares of Galena Biopharma Inc (NASDAQ:GALE) ended Tuesday session in green amid volatile trading. The shares closed up +0.06 points or 4.55% at $1.38 with 1.47 million shares getting traded. Post opening the session at $1.36, the shares hit an ...and more »
05/10/16 02:43 PMPerformance Recap and Target Perspective on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - B.O.D.Y Confidential - Performance Recap and Target Perspective on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)B.O.D.Y ConfidentialIn the latest trading session, shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) moved +3.31%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check, ...and more »
05/10/16 02:43 PMAnthera Pharmaceuticals Inc's Stock Is Buy After Today's Huge Increase - B.O.D.Y Confidential - Anthera Pharmaceuticals Inc's Stock Is Buy After Today's Huge IncreaseB.O.D.Y ConfidentialThe stock of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) is a huge mover today! The stock is up 8.97% or $0.28 after the news, hitting $3.4 per share. About 432,799 shares traded hands. Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has declined ...Jefferies Thinks Anthera Pharmaceuticals' Stock is Going to RecoverMarkets.coall 2 news articles »
05/10/16 02:43 PMStock Update (NASDAQ:ANTH): Anthera Pharmaceuticals Inc Provides Business Update and Reports 2016 First ... - Smarter Analyst - Smarter AnalystStock Update (NASDAQ:ANTH): Anthera Pharmaceuticals Inc Provides Business Update and Reports 2016 First ...Smarter AnalystIn this role, Mr. Thompsonwill oversee both our late stage development programs and launch readiness efforts. Mr. Thompson joins Anthera with over 20 years of experience in pharmaceutical development and commercialization. Most recently he served as ...Anthera Pharmaceuticals Inc (ANTH) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPSNewsWay 21Earnings Review: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) moved down 16 times out of last 27 quartersZergwatchAnthera Pharmaceuticals Reports Wider Year-Over-Year Q1 Loss (NASDAQ:ANTH)Sonoran Weekly ReviewWeb Breaking News -The Post -Risers & Fallersall 7 news articles »
05/10/16 12:04 PMANTHERA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -
05/09/16 07:51 PMCheck on Analyst Ratings Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - B.O.D.Y Confidential - Check on Analyst Ratings Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 1 on shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to 5 ...and more »
05/09/16 07:51 PMBRIEF-Anthera Pharmaceuticals posts Q1 loss of $0.29/share - Reuters - BRIEF-Anthera Pharmaceuticals posts Q1 loss of $0.29/shareReutersMay 9 Anthera Pharmaceuticals Inc : * Anthera Pharmaceuticals provides business update and reports 2016 first quarter financial results. * Q1 loss per share $0.29. * Says license and collaborative revenues for quarter ended March 31, 2016 totaled $145 ...
05/09/16 02:44 PMAnthera Pharmaceuticals Provides Business Update and Reports 2016 First Quarter Financial Results - GlobeNewswire (press release) - Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quarter Financial ResultsGlobeNewswire (press release)In this role, Mr. Thompson will oversee both our late stage development programs and launch readiness efforts. Mr. Thompson joins Anthera with over 20 years of experience in pharmaceutical development and commercialization. Most recently he served as ...
05/09/16 07:58 AMAnthera Pharmaceuticals Provides Business Update and Reports 2016 First Quarter Financial Results - [at noodls] - SOLUTION clinical study of Sollpura™ expanded to Europe, Israel and Canada in addition to ongoing US enrollment Craig Thompson named as President and Chief Operating Officer Appointment of Dr. James Pennington ...
05/09/16 07:47 AMAnthera reports 1Q loss -
05/09/16 07:41 AM8:41 am Anthera Pharma reports Q1 EPS of ($0.29) vs ($0.28) Capital IQ Consensus Estimate; co did not report any revs -
05/09/16 06:07 AMQ1 2016 Anthera Pharmaceuticals Inc Earnings Release - Before Market Open -
About Anthera Pharmaceuticals

Anthera Pharmaceuticals logoAnthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company's primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Company's second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ANTH
  • CUSIP:
Key Metrics:
  • Previous Close: $3.10
  • 50 Day Moving Average: $3.39
  • 200 Day Moving Average: $3.62
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $129.93M
  • Current Quarter EPS Consensus Estimate: $-1.25 EPS
Additional Links:
Anthera Pharmaceuticals (NASDAQ:ANTH) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha